CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Revance Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Revance Therapeutics Inc
1222 Demonbreun Street, Suite 2000
Phone: (615) 724-7755p:615 724-7755 NASHVILLE, TN  37203  United States Ticker: RVNCRVNC

Business Summary
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings. The Company’s aesthetics portfolio of expertly created products and services, including DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind relational commerce platform for aesthetic practices. The Company’s therapeutics pipeline is focused on muscle movement disorders, including evaluating DAXXIFY in two debilitating conditions, cervical dystonia and upper limb spasticity. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient along with the other excipients. DAXXIFY a commercially approved product, is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Angus C.Russell 67 3/4/2014 3/4/2014
President Dustin S.Sjuts 43 11/9/2021 3/1/2018
Chief Executive Officer, Director Mark J.Foley 57 11/9/2021 9/5/2017
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Hint, Inc. 7901 Stoneridge Dr Pleasanton CA United States

Business Names
Business Name
Hint, Inc.
Revance International Limited
Revance Therapeutics LTD
Revance Therapeutics Ltd.
RVNC

General Information
Number of Employees: 534 (As of 12/31/2022)
Outstanding Shares: 104,215,614 (As of 3/8/2024)
Shareholders: 180
Stock Exchange: NASD
Federal Tax Id: 770551645
Fax Number: (302) 655-5049
Email Address: info@revance.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024